ADHD affects nearly 6.1 million children in the U.S. Incidence is 11% and growing in children aged 4 to 17 years of age — and an estimated 50% of those cases may persist into adulthood. ADHD and related conditions have traditionally been managed with pharmacotherapy, behavioral therapy, or a combination of the two. However, up to 30% of patients do not respond to stimulant medications, and there are concerns and controversies surrounding the side effects and long-term safety of such drugs. Research over the past 40 years has shown that children with ADHD have significantly lower levels of essential fatty acids in their brains. Due to genetic differences in the way they metabolize dietary fats, they are not able to rebalance this from the diet alone. These deficiencies are thought to affect cell membrane structure and integrity, which in turn affects the regulation of crucial signaling molecules and inflammatory pathways in the brain. In this webinar, you’ll:
- Understand the prevalence of neurodevelopmental disorders with a special focus on ADHD
- Learn about the ‘neurodiversity’ paradigm and self-empowerment: a strength-based approach
- Gain insights into an inclusive approach to treatment, covering traditional, lifestyle, and nutritional interventions.
- Be introduced to EQUAZEN® PRO and review the practical applications of this medical food designed to address differences in omega-fatty acid metabolism in children and adolescents with ADHD.†
- The ADHD Omega Fatty Acid Connection Webinar Slides
- Healthcare Professional ADHD Resource Kit
- Parent’s ADHD Resource Kit